Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Andrea Seidel-Glaetzer"'
Autor:
Hans Salwender, Uta Bertsch, Katja Weisel, Jan Duerig, Christina Kunz, Axel Benner, Igor W. Blau, Marc Steffen Raab, Jens Hillengass, Dirk Hose, Stefanie Huhn, Michael Hundemer, Mindaugas Andrulis, Anna Jauch, Andrea Seidel-Glaetzer, Hans-Walter Lindemann, Manfred Hensel, Stefan Fronhoffs, Uwe Martens, Timon Hansen, Mohammed Wattad, Ullrich Graeven, Markus Munder, Roland Fenk, Mathias Haenel, Christof Scheid, Hartmut Goldschmidt
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of
Externí odkaz:
https://doaj.org/article/5f886bfc9cbd44f2ba2caaa95f24d69d
Autor:
Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M. Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, K. Martin Kortüm, Carsten Müller-Tidow, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Niels Weinhold, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab
Publikováno v:
Blood. 141:1685-1690
Activating BRAF mutations are found in a small subset of patients with newly diagnosed multiple myeloma, but prevalence increases in late-stage, refractory disease, and the mutations are associated with adverse outcome. This prospective single-arm, o
Autor:
Nicola, Giesen, Manik, Chatterjee, Christof, Scheid, Alexandra M, Poos, Britta, Besemer, Kaya, Miah, Axel, Benner, Nicole, Becker, Thomas, Moehler, Ivana, Metzler, Cyrus, Khandanpour, Andrea, Seidel-Glaetzer, Karolin, Trautmann-Grill, K Martin, Kortüm, Carsten, Müller-Tidow, Gunhild, Mechtersheimer, Benjamin, Goeppert, Albrecht, Stenzinger, Niels, Weinhold, Hartmut, Goldschmidt, Katja C, Weisel, Marc S, Raab
Publikováno v:
Blood.
Activating BRAF mutations are found in a small subset of patients with newly diagnosed multiple myeloma but prevalence increases in late stage, refractory disease, and are associated with adverse outcome. This prospective single-arm, open-label, mult
Autor:
Kaya Miah, Christof Scheid, Christina Kunz, Stephan Kremers, Elias K. Mai, Mathias Haenel, Rolf Mahlberg, Jana Schlenzka, Markus Munder, Andreas Neubauer, Hartmut Goldschmidt, Katja Weisel, Ullrich Graeven, Igor Wolfgang Blau, Stefanie Huhn, Aneta Schieferdecker, Jan Dürig, Uwe M. Martens, Manfred Hensel, Dirk Hose, Anna Jauch, Roland Schroers, Peter Reimer, Christian Kunz, Andrea Seidel-Glaetzer, Uta Bertsch, Marc-Steffen Raab, Ivana von Metzler, Britta Besemer, Hans Salwender, Joerg Thomalla, Roland Fenk
Publikováno v:
Blood. 138:486-486
Background: Treatment regimens including a proteasome inhibitor, immunomodulating agent and a monoclonal antibody (moAb) play an emerging role in the treatment of newly-diagnosed multiple myeloma (NDMM). This multicenter phase III trial of the German
Autor:
Hartmut Goldschmidt, Cyrus Khandanpour, Manik Chatterjee, Britta Besemer, Karolin Trautmann-Grill, Christof Scheid, Gunhild Mechtersheimer, Marc S. Raab, Katja Weisel, Nicola Giesen, Albrecht Stenzinger, Ivana von Metzler, Axel Benner, Kaya Miah, Andrea Seidel-Glaetzer, Benjamin Goeppert
Publikováno v:
Blood. 136:44-45
Introduction: The treatment of patients (pts) with rrMM remains challenging and response is often limited in depth and duration. In contrast to many other malignant diseases, targeted therapy in MM is hampered by the limited number of actionable targ
Autor:
Igor Wolfgang Blau, Katja Weisel, Jan Duerig, Mathias Haenel, Roland Fenk, Uta Bertsch, Christina Kunz, Stefanie Huhn, Marc S. Raab, Hartmut Goldschmidt, Uwe M. Martens, Ullrich Graeven, Manfred Hensel, Stefan Fronhoffs, Jens Hillengass, Mohammed Wattad, Hans Salwender, Markus Munder, Anna Jauch, Hans-Walter Lindemann, Timon Hansen, Dirk Hose, Christof Scheid, Axel Benner, Mindaugas Andrulis, Michael Hundemer, Andrea Seidel-Glaetzer
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Background: Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of new drug
Autor:
Hartmut Goldschmidt, Hans-Juergen Salwender, Markus Munder, Jens Hillengass, Patrick Wuchter, Mathias Haenel, Katharina Lisenko, Roland Fenk, Christof Scheid, Marc S. Raab, Axel Benner, Ullrich Graeven, Uta Bertsch, Igor Wolfgang Blau, Anthony D. Ho, Marc Andrea Baertsch, Andrea Seidel-Glaetzer, Jan Duerig, Katja Weisel, Natalia Becker
Publikováno v:
Blood. 128:3373-3373
Introduction: The German-Speaking Myeloma Multicenter Group (GMMG) has initiated a randomized multicenter phase III trial on the effect of elotuzumab in VRD (bortezomib, lenalidomide, dexamethasone) induction/consolidation and lenalidomide maintenanc